Arctoris is a platform company founded and headquartered in Oxford, UK that conducts integrated drug discovery projects from idea to IND. Ulysses, the unique technology platform developed by Arctoris, enables the company and its partners to conduct their R&D – from target validation via hit finding and hit-to-lead to lead optimization and beyond – significantly faster, and with considerably improved data quality and depth. Thanks to end-to-end automation of research processes, Arctoris generates more than 100 times more datapoints per assay than industry standard, making critical information in cell and molecular biology as well as biochemistry/ biophysics available earlier. Combining the expertise of seasoned biotech and pharma veterans with its proprietary technologies, Arctoris leads to higher success rates and an accelerated progression of programs towards the clinic. Arctoris offers both fee-for-service and risk-share agreements in small molecule and biologics discovery, and is trusted by biotech and pharma companies in the US, UK, Germany, Australia, Korea, Hong Kong, and many other countries. For more information, contact Martin-Immanuel Bittner MD DPhil FRSA, CEO: martin-immanuel.bittner@arctoris.com.
